In Segment A, members will acquire distinct doses and schedules of oral ABBV-744 pill to identify Risk-free dosing program. Extra members might be enrolled in the determined monotherapy dosign routine. In Phase B, contributors will receive oral ruxolitinib and ABBV-744 will likely be specified as "add-on" therapy. In Segment C, https://clinical-trial-recruitmen68012.anchor-blog.com/12334731/the-fact-about-new-advancements-in-brd4-inhibition-therapy-abbv-744-that-no-one-is-suggesting